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combined in- and outpatient observational study in
Germany. 646 adult schizophrenia patients treated with
either olanzapine (N = 416) or haloperidol (N = 230)
were enrolled in the study and quarterly observations on
the disease course, resource consumption and quality of
life are made during the follow-up period. RESULTS: In
both treatment groups nearly 50% of the patients were
female, had been diagnosed around the age of 30 years,
and were overweight (BMI > 25). Hospital inpatients and
hospital day care patients were more severely ill (N = 230,
>50% with CGI clearly ill or worse) than outpatients (N
= 416, >50% with CGI moderate or better). For both
treatment groups the global disease severity was similar
(approximately 70% moderate or worse, 15% severe or
worse) as well as the existence of positive symptoms
(about 64% had current positive symptoms in both
groups). Olanzapine patients were younger (mean 39 vs.
46 years). Current negative symptoms (90% vs. 98%)
and cognitive symptoms (88% vs. 95%) were less
common for olanzapine patients than for haloperidol
patients, whereas depressive symptoms were more
common (75% vs. 69%). More olanzapine patients were
able to care for themselves (87% vs. 78%) and lived at
home without care (57% vs. 40%). More olanzapine
patients were employed (32% vs. 18%) and fewer were
in early retirement (27% vs. 46%). CONCLUSIONS: At
time of enrolment in the GEO observational study 
olanzapine and haloperidol-treated patients had schizo-
phrenia of similar severity but different disease course.
Fewer olanzapine patients had negative or cognitive
symptoms whereas more had depressive symptoms. More
olanzapine patients were employed and able to care for
themselves, whereas more haloperidol patients were in
early retirement.
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OBJECTIVES: To provide a study description and 
baseline socio-demographic, socio-economic and clinical
characteristics of schizophrenia patients treated with
haloperidol, olanzapine or risperidone at time of 
enrolment in the SOS observational study. METHODS:
SOS is a non-randomised 2-year prospective observa-
tional study. Data are collected on treatment costs, 
efﬁcacy, tolerability and patient quality of life using an
internet-based case report form on patients assigned treat-
ment with haloperidol, olanzapine or risperidone during
a recent psychotic episode requiring hospitalisation.
Patients were included within one month from discharge
to part-time hospitalisation or ambulatory care if treat-
ment with the study drug was stable since at least a
month. Data are collected at inclusion and after 3, 6, 12,
18 and 24 months. RESULTS: 323 patients diagnosed
with schizophrenia or schizofreniform disorders (DSM-
IV criteria) have been enrolled in the study. Preliminary
baseline data on 305 patients (males: 65%) show that 32
patients are on haloperidol, 141 on olanzapine and 132
on risperidone. 77% are outpatients. 57% suffer para-
noid schizophrenia. Mean age is 37 ± 13y. The socio-
economic proﬁle (living environment, schooling back-
ground and working activity) is comparable between
treatment groups. “Brief Psychiatric Rating Scale” and
“Clinical Global Impression” scores (overall mean: 32 ±
16 and 4.0 ± 1.2 respectively) are comparable for all
groups. However, some variables such as ﬁrst antipsy-
chotic prescription (haloperidol: 6.3%; olanzapine: 18%;
risperidone: 24%) suggest that there may be differences
between the treatment groups. “Global Assessment of
Functioning” score (mean: 52 ± 14) is signiﬁcantly lower
in the haloperidol group (47 ± 12). General quality of life
(EQ-5D) is comparable for all groups (66 ± 19). “Sub-
jective Well-Being under Neuroleptics” scores are signiﬁ-
cantly worse in the olanzapine group. CONCLUSION:
The SOS observational study will provide substantial
information to increase the understanding of the clinical,
social and economic outcomes and current treatment
modalities in real world clinical practice in the treatment
of schizophrenia in Belgium.
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OBJECTIVE: To compare incidence rates of hyperlipi-
demia among schizophrenia patients treated with 
conventional or newer antipsychotics. METHODS: Inte-
grated claims from a large insured population were used.
Analysis included 614 individuals who: were diagnosed
with schizophrenia (ICD9 295.xx); initiated a typical
antipsychotic, or olanzapine or risperidone; had no use
of any antipsychotics in the prior 6 months. New onset
hyperlipidemia was deﬁned as either two hyperlipidemia
diagnoses (ICD9 272.xx) or prescription for lipid-
lowering agents. One-year incidence rates were compared
using logistic regressions controlling for demographics
and medical comorbidities. Cox proportional hazard
method and Kaplan-Meier survival curves of time-to-
incidence were compared between treatment groups.
RESULTS: Adjusted odds ratios of incidence of hyper-
lipidemia (based on diagnosis and/or treatment) were:
atypical vs. typical 1.684 (p = 0.32); risperidone vs.
typical 1.622 (p = 0.42); olanzapine vs. typical 1.878 
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(p = 0.26); and olanzapine vs. risperidone 1.084 (p =
0.87). Furthermore, adjusted odds ratios of being treated
with a lipid-lowering agent were: atypical vs. typical
1.553 (p = 0.46); risperidone vs. typical 1.711 (p = 0.42);
olanzapine vs. typical 1.474 (p = 0.55); and olanzapine
vs. risperidone 0.775 (p = 0.66). CONCLUSION: Based
on a claims database, 1-year incidence of hyperlipidemia
was generally comparable in schizophrenia patients
receiving treatment with typical antipsychotics, olanzap-
ine or risperidone, though typical-treated patients had
numerically lower incidence compared to those atypical-
treated patients.
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OBJECTIVES: To investigate the association between
sexual dysfunction and nonadherence with antipsychotic
therapy in individuals with schizophrenia. METHODS:
In June 2001, 842 individuals with schizophrenia com-
pleted a self-administered questionnaire that included
questions about the side effects of antipsychotic therapy.
Respondents rated frequency of sexual dysfunction as 
a medication side effect, as well as the degree of dis-
tress and general satisfaction with sexual health and
sexual relationships. Therapeutic nonadherence (non-
compliance) was scored by the self-reported frequency of
missed or skipped antipsychotic doses in an average week.
The association between sexual dysfunction and adher-
ence was evaluated through bivariate analysis and a mul-
tivariate linear regression model, which included Drug
Attitude Inventory (DAI) scores, demographic factors,
and the use of other classes of psychotropic medications.
RESULTS: Among self-reported side effects, distress from
sexual dysfunction was very common. It proved second
only to weight gain in the degree of distress reported by
respondents. A negative association was also found
between reported sexual dysfunction and satisfaction
with sexual health and sexual relationships (P < 0.001).
Sexual dysfunction was associated with self-reported 
nonadherence, both in bivariate analysis (P = 0.024) and
multivariate linear regression (P = 0.035). CONCLU-
SION: In this survey, sexual dysfunction was associated
with reduced adherence to antipsychotic therapy. These
data underscore the importance of assessing side 
effects related to sexual function in patients receiving
antipsychotics.
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OBJECTIVE: To evaluate sample differences associated
with recruiting strategies in a study of people with 
schizophrenia. METHODS: In June 2000 and 2001, 
participants were identiﬁed through Community Mental
Health Centers (CMHC) and chapters of the National
Alliance for the Mentally Ill (NAMI) for a study designed
to understand, explain, and predict the healthcare 
attitudes and behaviors of people with schizophrenia.
Data were collected using self-administered question-
naires. RESULTS: As expected, CMHC (n = 416) and
NAMI (n = 430) respondents differed demographically.
CMHC respondents were more likely to be older (p <
0.001), non-white (p = 0.002), living in group homes (p
< 0.001), and concentrated in urban regions of the
country (Northeast and West, p < 0.001). CMHC respon-
dents were less likely than NAMI recruits to participate
in productive activities (p < 0.001). However, respondents
from both facilities had similar health histories. They
experienced schizophrenia symptoms for similar dura-
tions and had similar symptom severity, as measured by
the Psychological General Well-Being (PGWB) scale. The
two groups were also equally as likely to be overweight
or obese, diagnosed with high cholesterol, and to use
alcohol. CMHC and NAMI respondents also had similar
patterns of care. They were equally as likely to have been
hospitalized in the past six months and to be insured by
Medicaid. Most respondents from both groups were
treated with atypical antipsychotics and received mental
healthcare from community mental health centers. The
groups had almost identical attitudes about medication
compliance (p = 0.989), as measured by the Drug Atti-
tude Inventory (DAI). They also had similar medication
compliance behaviors; 32% of CMHC recruits and 38%
from NAMI organizations reported at least occasionally
missing their psychotropic medication (p = 0.118). 
CONCLUSION: Despite large demographic differences
between respondents recruited through NAMI and
CMHC, there were few differences in health history, and
no signiﬁcant differences in patterns of schizophrenia
care.
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